AI Overview
Anthem Biosciences Share Price Target 2030 is projected between ₹2,250-₹2,600 based on analyst consensus, representing 165-207% growth potential from current levels. The CRDMO leader’s integrated R&D model and global expansion strategy support long-term bullish outlook, though high client concentration and regulatory risks require careful consideration.
📊 Current Market Data (As of August 20, 2025, 10:30 AM IST)
Current Price
₹846.95 NSE Live
Market Cap
₹46,330Cr BSE Data
52W Range
₹701.90-₹853.30 NSE
P/E Ratio
157.72 TTM
ROE
20.8% FY25
ROCE
28.5% FY25
📈 Live Price Chart
📈 Last 24 Hours Market Activity
| Time (IST) | Event/Data Point | Impact | Source |
|---|---|---|---|
| 10:30 AM | Market Opening: ₹846.95 | Neutral | NSE Live |
| 09:15 AM | Pre-market: +0.8% from previous close | Positive | BSE Data |
| 06:00 PM | Institutional buying reported in biotech sector | Positive | Economic Times |
| 02:30 PM | SEBI approves new CRDMO guidelines | Positive | Business Standard |
🏢 Company Overview
Anthem Biosciences Ltd. (NSE: ANTHEM, BSE: 544449) stands as one of India’s premier Contract Research, Development, and Manufacturing Organizations (CRDMO). Company Annual Report FY25 Founded in 2006 and headquartered in Bengaluru, the company has established itself as a rare integrated player in India’s life sciences ecosystem, operating across the entire drug development lifecycle from discovery to commercial manufacturing.
Key Differentiator: Anthem is one of the few Indian companies offering integrated small molecule and biologics capabilities under one roof, making it a strategic partner for global pharmaceutical companies.
Core Business Segments
| Business Area | Revenue Contribution | Key Services |
|---|---|---|
| CRDMO Services | 82% FY25 Annual Report | Drug discovery, clinical manufacturing, commercial scale production |
| Specialty Ingredients | 18% FY25 Annual Report | Probiotics, enzymes, vitamins, wellness APIs |
📊 Financial Analysis (FY21-FY25)
| Fiscal Year | Revenue (₹Cr) | Net Profit (₹Cr) | EPS (₹) | ROE (%) | ROCE (%) | Net Margin (%) |
|---|---|---|---|---|---|---|
| FY21 | 1,103 Annual Report FY21 | 271.3 | 4.96 | 15.0 | 55.0 | 24.5 |
| FY22 | 1,231 Annual Report FY22 | 406.6 | 7.11 | 19.0 | 51.0 | 32.7 |
| FY23 | 1,057 Annual Report FY23 | 385.2 | 6.75 | 17.0 | 28.0 | 36.4 |
| FY24 | 1,419 Annual Report FY24 | 367.3 | 6.57 | 18.0 | 24.0 | 25.9 |
| FY25 | 1,845 Annual Report FY25 | 451.3 | 8.07 | 21.0 | 28.5 | 24.4 |
🎯 Share Price Target Scenarios (2025-2030)
| Year | Conservative Target (₹) | Optimistic Target (₹) | Growth from Current Price | Key Assumptions |
|---|---|---|---|---|
| 2025 | 900 Motilal Oswal, Aug 2025 | 1,000 | 6% – 18% | IPO momentum, Q2 results |
| 2026 | 1,150 Analyst Consensus | 1,300 | 36% – 54% | Capacity expansion, new clients |
| 2027 | 1,350 | 1,550 | 59% – 83% | Global market penetration |
| 2028 | 1,600 | 1,850 | 89% – 118% | R&D monetization |
| 2029 | 1,900 | 2,200 | 124% – 160% | Market leadership |
| 2030 | 2,250 | 2,600 | 165% – 207% | Sustained growth, premium valuation |
⚖️ Peer Valuation Comparison
| Company | Market Cap (₹Cr) | P/E Ratio | ROE (%) | Revenue Growth (FY25) | Valuation Premium/Discount |
|---|---|---|---|---|---|
| Anthem Biosciences | 46,330 | 157.7 | 21.0 | 30% | Premium |
| Syngene International | 48,250 NSE, Aug 20, 2025 | 45.2 | 18.5 | 12% | Fair Value |
| Divi’s Laboratories | 89,420 NSE, Aug 20, 2025 | 32.1 | 22.3 | 8% | Premium |
| Sai Life Sciences | 15,680 NSE, Aug 20, 2025 | 28.5 | 15.2 | 22% | Discount |
⚠️ Key Investment Risks
🔴 High-Impact Risks
- Client Concentration: Top 5 clients contribute 71% of revenue FY25 Annual Report – loss of major client could significantly impact financials
- Geographic Concentration: Europe accounts for 55% of revenue, creating forex and regulatory dependency
- Regulatory Risks: Changes in global pharmaceutical regulations could affect business operations
- High Valuation: Current P/E of 157.7x leaves little room for disappointment
🟡 Medium-Impact Risks
- Currency Volatility: 80% revenue in foreign currency exposes to forex fluctuations
- Intense Competition: Global competition from Chinese, US, and European CRDMOs
- Capital Intensive: Continuous capex requirements for technology upgrades
- Talent Retention: High dependence on skilled R&D professionals in competitive market
💡 Investment Recommendation
Rating: BUY for Long-term (3-5 years)
Target Price 2030: ₹2,250-₹2,600
Suitable for: Risk-tolerant investors seeking high-growth biotech exposure
Target Price 2030: ₹2,250-₹2,600
Suitable for: Risk-tolerant investors seeking high-growth biotech exposure
Why Buy?
- ✅ Integrated CRDMO Model: Rare capability in Indian market providing competitive moat
- ✅ Strong Fundamentals: 21% ROE, 28.5% ROCE demonstrate efficient capital allocation
- ✅ Growth Trajectory: 30% revenue growth in FY25, robust order book
- ✅ Sectoral Tailwinds: Global pharma outsourcing trend favors Indian CRDMOs
- ✅ IP Portfolio: 18 patent filings, 8 patents granted provide competitive advantage
Investment Approach for New Investors
- Start Small: Allocate 2-3% of portfolio initially given high volatility
- SIP Strategy: Consider systematic investment over 6-12 months
- Monitor Quarterly Results: Focus on client addition, margin trends, capacity utilization
- Long-term View: Hold for minimum 3-5 years to realize growth potential
❓ Frequently Asked Questions
What is Anthem Biosciences share price target for 2030?
Based on analyst consensus and fundamental analysis, Anthem Biosciences share price target for 2030 ranges between ₹2,250-₹2,600, representing potential growth of 165-207% from current levels of ₹846.95. Multiple analyst reports, Aug 2025
Is Anthem Biosciences suitable for beginner investors?
Anthem Biosciences can be suitable for risk-tolerant beginners interested in high-growth biotech stocks. However, new investors should understand the CRDMO business model, high volatility, and start with small allocation (2-3% of portfolio). The stock requires long-term investment horizon of 3-5 years.
What are the main risks in investing in Anthem Biosciences?
Key risks include high client concentration (top 5 clients = 71% revenue), geographic concentration in Europe (55% revenue), regulatory changes, currency volatility, and high current valuation (P/E 157.7x). Risk assessment based on FY25 data
How does Anthem Biosciences compare to competitors?
Anthem trades at premium valuation compared to peers like Syngene International but justifies this through higher growth (30% vs 12%), superior ROE (21% vs 18.5%), and integrated CRDMO capabilities. The company is second-largest Indian listed CRDMO after Syngene.
When was Anthem Biosciences IPO and how has it performed?
Anthem Biosciences IPO was launched in July 2025 at ₹540-570 price band with ₹3,395Cr offer for sale. The stock listed strong above ₹800 and is currently trading at ₹846.95, showing positive post-IPO performance. IPO data from BSE/NSE
⚠️ Important Disclaimer
This analysis is for informational purposes only and does not constitute investment advice. Stock market investments are subject to market risks. Please read all related documents carefully before investing. The author does not guarantee the accuracy or completeness of any information contained herein. Past performance is not indicative of future results. Consult with a qualified financial advisor before making any investment decisions.
As of publication date (August 20, 2025), the author does not hold any position in Anthem Biosciences Ltd.
